Chimiothérapie locorégionale des métastases hépatiques du cancer colo-rectal.

P. Rougier; P. Lasser; J. P. Droz; D. Elias; M. Ghosn; M. Ducreux; J. Lumbroso; S. Sidibe

Chimiothérapie locorégionale des métastases hépatiques du cancer colo-rectal.

Translated title of the contribution: Locoregional chemotherapy of hepatic metastases of colorectal cancer

P. Rougier, P. Lasser, J. P. Droz, D. Elias, M. Ghosn, M. Ducreux, J. Lumbroso, S. Sidibe

Research output: Contribution to journal › Article › peer-review

Abstract

Locoregional, intra-arterial chemotherapy of liver metastases secondary to colo-rectal cancers is the least damaging among non-surgical treatments. In our experience of 58 cases treated during three years either with intermittent perfusions of 5 FU, or with continuous perfusion of FUDR (by pump), we observed 52% and 53% of objective responses with a survival rate at one year, of 73% and 90% respectively. However, this technique is limited because of locoregional complications and less effective, due to the development of extra-hepatic metastases. The proof of its effectiveness, in terms of survival, is currently being studied in the scope of a prospective and randomized trial with control group.

Translated title of the contribution	Locoregional chemotherapy of hepatic metastases of colorectal cancer
Original language	French
Pages (from-to)	315-319
Number of pages	5
Journal	Annales de Gastroenterologie et d'Hepatologie
Volume	23
Issue number	6
Publication status	Published - 1 Jan 1987

Cite this

@article{a169bb2e58ac4d90b7ae339499f5d79a,

title = "Chimioth{\'e}rapie locor{\'e}gionale des m{\'e}tastases h{\'e}patiques du cancer colo-rectal.",

abstract = "Locoregional, intra-arterial chemotherapy of liver metastases secondary to colo-rectal cancers is the least damaging among non-surgical treatments. In our experience of 58 cases treated during three years either with intermittent perfusions of 5 FU, or with continuous perfusion of FUDR (by pump), we observed 52% and 53% of objective responses with a survival rate at one year, of 73% and 90% respectively. However, this technique is limited because of locoregional complications and less effective, due to the development of extra-hepatic metastases. The proof of its effectiveness, in terms of survival, is currently being studied in the scope of a prospective and randomized trial with control group.",

author = "P. Rougier and P. Lasser and Droz, {J. P.} and D. Elias and M. Ghosn and M. Ducreux and J. Lumbroso and S. Sidibe",

year = "1987",

month = jan,

day = "1",

language = "Fran{\c c}ais",

volume = "23",

pages = "315--319",

journal = "Annales de Gastroenterologie et d'Hepatologie",

issn = "0066-2070",

number = "6",

}

TY - JOUR

T1 - Chimiothérapie locorégionale des métastases hépatiques du cancer colo-rectal.

AU - Rougier, P.

AU - Lasser, P.

AU - Droz, J. P.

AU - Elias, D.

AU - Ghosn, M.

AU - Ducreux, M.

AU - Lumbroso, J.

AU - Sidibe, S.

PY - 1987/1/1

Y1 - 1987/1/1

N2 - Locoregional, intra-arterial chemotherapy of liver metastases secondary to colo-rectal cancers is the least damaging among non-surgical treatments. In our experience of 58 cases treated during three years either with intermittent perfusions of 5 FU, or with continuous perfusion of FUDR (by pump), we observed 52% and 53% of objective responses with a survival rate at one year, of 73% and 90% respectively. However, this technique is limited because of locoregional complications and less effective, due to the development of extra-hepatic metastases. The proof of its effectiveness, in terms of survival, is currently being studied in the scope of a prospective and randomized trial with control group.

AB - Locoregional, intra-arterial chemotherapy of liver metastases secondary to colo-rectal cancers is the least damaging among non-surgical treatments. In our experience of 58 cases treated during three years either with intermittent perfusions of 5 FU, or with continuous perfusion of FUDR (by pump), we observed 52% and 53% of objective responses with a survival rate at one year, of 73% and 90% respectively. However, this technique is limited because of locoregional complications and less effective, due to the development of extra-hepatic metastases. The proof of its effectiveness, in terms of survival, is currently being studied in the scope of a prospective and randomized trial with control group.

UR - http://www.scopus.com/inward/record.url?scp=0023445968&partnerID=8YFLogxK

M3 - Article

C2 - 2962534

AN - SCOPUS:0023445968

SN - 0066-2070

VL - 23

SP - 315

EP - 319

JO - Annales de Gastroenterologie et d'Hepatologie

JF - Annales de Gastroenterologie et d'Hepatologie

IS - 6

ER -

Chimiothérapie locorégionale des métastases hépatiques du cancer colo-rectal.

Abstract

Other files and links

Cite this